<SEC-DOCUMENT>0001104659-17-036180.txt : 20170530
<SEC-HEADER>0001104659-17-036180.hdr.sgml : 20170530
<ACCEPTANCE-DATETIME>20170530162413
ACCESSION NUMBER:		0001104659-17-036180
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20170530
DATE AS OF CHANGE:		20170530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gemphire Therapeutics Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-217296
		FILM NUMBER:		17877693

	BUSINESS ADDRESS:	
		STREET 1:		17199 N. LAUREL PARK DRIVE
		STREET 2:		SUITE 401
		CITY:			LIVONIA
		STATE:			MI
		ZIP:			48152
		BUSINESS PHONE:		248-980-6538

	MAIL ADDRESS:	
		STREET 1:		17199 N. LAUREL PARK DRIVE
		STREET 2:		SUITE 401
		CITY:			LIVONIA
		STATE:			MI
		ZIP:			48152
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>a17-14414_2424b3.htm
<DESCRIPTION>424B3
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Filed   Pursuant to Rule&nbsp;424(b)(3)</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Registration   No.&nbsp;333-217296</font></b></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.25pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Prospectus Supplement No.&nbsp;3</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(to Prospectus dated April&nbsp;21, 2017)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2,317,460 Shares</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="227" height="128" src="g144142bci001.jpg"></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Gemphire Therapeutics&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Common Stock</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus supplement supplements the prospectus dated April&nbsp;21, 2017 (the &#147;Prospectus&#148;), which forms a part of our Registration Statement on Form&nbsp;S-1 (Registration No.&nbsp;333-217296). This prospectus supplement is being filed to update and supplement the information in the Prospectus with information contained in our Current Report on Form&nbsp;8-K, filed with the Securities and Exchange Commission on May&nbsp;30, 2017 (the &#147;Current Report&#148;). Accordingly, we incorporate by reference the Current Report into this prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Prospectus and this prospectus supplement relate to the resale, from time to time, of up to 2,317,460 shares of common stock of Gemphire Therapeutics Inc. (the &#147;Company&#148;) by the selling stockholders listed on page&nbsp;10 of the Prospectus, which includes (i)&nbsp;1,324,256 shares of our common stock, par value $0.001 per share (the &#147;Common Stock&#148;) issued on March&nbsp;15, 2017 and (ii)&nbsp;an aggregate of 993,204 shares of our Common Stock (the &#147;Warrant Shares&#148;) issuable upon exercise of common stock purchase warrants issued on March&nbsp;15, 2017 (the &#147;Warrants&#148;) by the selling stockholders listed on page&nbsp;10 of the Prospectus, including their transferees, pledgees or donees or their respective successors (the &#147;Selling Stockholders&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus supplement should be read in conjunction with the Prospectus. This prospectus supplement updates and supplements the information in the Prospectus. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our Common Stock trades on the NASDAQ Global Market under the symbol &#147;GEMP&#148;. On May&nbsp;26, 2017, the last reported sale price per share of our Common Stock was $10.50 per share.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements for the Prospectus, this prospectus supplement and future filings.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Investing in our Common Stock involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page&nbsp;6 of the Prospectus.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The date of this prospectus supplement is May&nbsp;30, 2017.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108202\17-14414-2\task8454076\14414-2-bc.htm',USER='108202',CD='May 31 01:22 2017' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g144142bci001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g144142bci001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "  .,# 2(  A$! Q$!_\0
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MH.26NY/,>JDA1DD #N:175UW(P8>H.:\]\<75Y'X?CWW,ULLF([>W0_O)/\
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M8M-L(+2W7$4*!5KG_$G@F'7M3@U".[EM+N)0H=.>AR/QYK155*HY2%;2QU/
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GM%%%9#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
